ODA

Global Rare Hemophilia Factors (I, II, VII) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Health, Genetics, FDA, Child, Plasma, Second Continental Congress, Orphan Drug Act of 1983, Health care, Haemophilia, ODA, Hand, Treatment, Congress, Prevalence, VII, Coagulation factor VII, Personal protective equipment, Coagulation, Infection, Quality of life, Growth, COVID-19, Factor VII deficiency, Patient, Diagnosis, Speciality chemicals, Pharmaceutical industry, Tisagenlecleucel, Safety, Cryoprecipitate

The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.
  • This intensified focus on patient safety measures is expected to have enduring benefits for rare hemophilia factor administration.

MTN and Tecnotree Redefine Digital Customer Experience with Their Launch of Metamorphose on Tecnotree D-Stack

Retrieved on: 
Thursday, October 19, 2023
Professional Services, Data Management, Business, Technology, Software, 5G, Artificial Intelligence, Digital, Element, KPI-driven code analysis, Business support system, BSS, Education, OTT, DSPS, Health, ODA, Fintech, Diamond, TM Forum, API, Architectural engineering, Transformation, FTTX, Record, Eye, Metamorphosis, Management control system, Video game, Retail, Online shopping, MTN, Tecnotree, MTN Group

Tecnotree, a global digital platform and services leader for 5G and cloud-native technology, proudly unveils the launch of MTN D-Stack, under the transformation program MTN Metamorphose powered by Tecnotree.

Key Points: 
  • Tecnotree, a global digital platform and services leader for 5G and cloud-native technology, proudly unveils the launch of MTN D-Stack, under the transformation program MTN Metamorphose powered by Tecnotree.
  • This ground-breaking project, driven by Tecnotree’s digital suite, marks a significant milestone in enhancing MTN presence for both consumers and enterprises, promising a new era of unparalleled digital service excellence.
  • Tecnotree BSS Suite will enable extraordinary transformation for MTN with capabilities that are in line with their goals and forge more powerful experiences that deliver greater customer loyalty.
  • The D-Stack go-live will enable dynamic and improved user experience with enhanced 360-degree customer view and omnichannel engagement.

Tecnotree Announces Signing of a Multi-Million Deal with an Emerging CSP from Africa to Deliver Digital BSS, Fintech & VAS Services

Retrieved on: 
Tuesday, October 17, 2023
Professional Services, Business, Technology, 5G, Networks, Artificial Intelligence, Diamond, Partnership, Health, Africa Scout Region (World Organization of the Scout Movement), Charge density, TM Forum, 3GPP, AI, Fintech, API, AIML, Mediation, G, Digital, Business support system, Education, CRM, OTT, BSS, DSPS, Digital wallet, ODA, VAS, Diwa, Mobile phone, Online shopping, Tecnotree

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced the signing of a new multimillion-dollar, five-year contract with an emerging telco services provider from the African Region, to provide a full digital BSS stack along with Fintech and Value-Added Services (VAS) services.

Key Points: 
  • Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced the signing of a new multimillion-dollar, five-year contract with an emerging telco services provider from the African Region, to provide a full digital BSS stack along with Fintech and Value-Added Services (VAS) services.
  • The agreement aims to facilitate seamless end-to-end order to cash services for retail and enterprise customers.
  • Tecnotree’s 5G-ready BSS suite is agile, cloud-native, and Diamond-certified by TM Forum for real-world Open APIs.
  • The deployment also includes customer value enablement via self-service enablement, partner loyalty services & gamification, real-time campaigns, Digital Wallet (DiWa) services, and new age digital VAS services.

Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth

Retrieved on: 
Tuesday, October 3, 2023
Orphan Drug Act of 1983, Fresh frozen plasma, Infection, Hand, Prevalence, Personal protective equipment, Health care, COVID-19, Quality of life, Haemophilia, Coagulation, Second Continental Congress, Congress, Plasma, ODA, VII, Patient, Child, Coagulation factor VII, Factor VII deficiency, Growth, Diagnosis, FDA, Treatment, Speciality chemicals, Pharmaceutical industry, Safety, Tisagenlecleucel

The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.

Key Points: 
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • The surge in the market is primarily attributed to the increased availability of tailored factor concentrates securing regulatory approvals, notably from the U.S. FDA.
  • Additionally, the rising adoption of prophylaxis treatment among patients is expected to be a significant growth driver in the coming years.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.

Briclinks Africa Plc “BTEL” selects Tecnotree Switch MVNO platform, DiWa and Moments B2B2X Marketplace to go-to-market and revenue monetization capabilities

Retrieved on: 
Wednesday, September 20, 2023
Payments, Data Management, Technology, Telecommunications, Software, Networks, Electronic Commerce, Savings Deposit Insurance Fund of Turkey, Workflow, Fintech, Communication, Partnership, Education, Business support system, Telco, Platinum, Service, OTT, Moment, DSPS, ODA, Diwa, Greenfield, Concert Communications Services, BSS, Sport, Vserv Digital Services, Mobile virtual network operator, Digital, API, Intelligent Network, Health, Intelligence, Real-time, Payment, TM Forum, Telephone, Video game, Online shopping, Mobile phone, Virtual, Middleware, Remittance, Tecnotree

Tecnotree’s Switch for MVNOs suite comprises a full range of business processes that support customer lifecycle and revenue management.

Key Points: 
  • Tecnotree’s Switch for MVNOs suite comprises a full range of business processes that support customer lifecycle and revenue management.
  • CEO Briclinks Africa Plc “BTEL” Mr. Mohammed Buhari said, “We are delighted to partner with Tecnotree on this transformative journey.
  • Tecnotree MVNO suite, DiWa Intelligent Fintech Platform, Moments B2B2X enables us to enhance our operational efficiency and cater to the ever-evolving market requirements.
  • Tecnotree DiWa Intelligent Fintech Platform shall enable Briclinks Africa Plc “BTEL” to take a big step forward for payments and financial services in Nigeria.

From AI to Patient Advocacy: The Comprehensive Orphan Drugs and Rare Diseases Conference: London, United Kingdom - October 9-10, 2023

Retrieved on: 
Saturday, September 23, 2023
Orphan Drug Act of 1983, Infection, Regenerative medicine, ODA, AI, Rare, Drug development, Patient, Conference, Marketing, Pharmaceutical industry

DUBLIN, Sept. 22, 2023 /PRNewswire/ -- ResearchAndMarkets.com announces the 4th Annual Orphan Drugs and Rare Diseases Conference , scheduled for October 9-10 in London, UK.

Key Points: 
  • DUBLIN, Sept. 22, 2023 /PRNewswire/ -- ResearchAndMarkets.com announces the 4th Annual Orphan Drugs and Rare Diseases Conference , scheduled for October 9-10 in London, UK.
  • This prestigious event offers an in-depth exploration into the ever-evolving world of orphan drugs, post the landmark 1983 Orphan Drug Act (ODA).
  • The conference will spotlight novel therapies addressing the diverse and unique challenges of rare diseases, recognizing the vital importance of meeting the pressing needs of patients.
  • It also seeks to address the current challenges facing the field, including constrained resources, the severity of these diseases, restricted patient access, and the prevalent knowledge gap in the realm of rare diseases.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

Incognito Software Systems Recognized in 2023 Gartner Market Guide for CSP Service Design and Orchestration Solutions

Retrieved on: 
Wednesday, September 13, 2023
Telecommunications, Software, Networks, Internet, Technology, VoIP, Mobile, Wireless, Other Technology, Broadband Forum, Incognito, Metro Ethernet, Gartner, GCI, OSS, MEF, CAO, SMB, IEEE, ODA, VNPT, CableLabs, DTW, SD, Verizon Communications, 3GPP, NTT, SAC, CSP, TM Forum

Incognito Software Systems Inc. , a leading global provider of automated OSS broadband management solutions for service providers, today announced its inclusion in the Gartner Market Guide for CSP Service Design and Orchestration Solutions (SD&O).

Key Points: 
  • Incognito Software Systems Inc. , a leading global provider of automated OSS broadband management solutions for service providers, today announced its inclusion in the Gartner Market Guide for CSP Service Design and Orchestration Solutions (SD&O).
  • This acknowledgement underscores Incognito’s commitment to helping communication service providers (CSPs) streamline operations and optimize service delivery with its Service Activation Center (SAC) platform.
  • As a result, they are progressively modernizing their inventory management and service fulfillment systems by adopting holistic end-to-end lifecycle approaches to service management.
  • “Incognito is proud to be included in the Gartner Market Guide and be recognized as a leader in delivering innovative service orchestration solutions that meet the evolving business needs of CSPs,” said Ronan Bracken, SAC Product Director at Incognito.

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

Retrieved on: 
Friday, August 25, 2023
Other Health, Research, General Health, Professional Services, Pharmaceutical, Oncology, Healthcare Reform, Science, Legal, Congressional News, Views, Health, Public Policy, Government, Orphan Drug Act of 1983, Eculizumab, REMS, Central nervous system, Drug development, Vaccination, Prostate cancer, GMG, Infection, Attenuated vaccine, Fever, JAMA, Cancer, Light, Neuromyelitis optica spectrum disorder, Breast, Medicine, NMOSD, IRA, AstraZeneca, Rash, American Medical Association, Neisseria meningitidis, Vomiting, Inflation, ODA, Low-probability-of-intercept radar, Meningococcal vaccine, Patient, Risk, Autoimmune disease, PNH, Immune system, Nausea, Confusion, Inflation Reduction Act of 2022, Rare, Headache, Patient safety, Death, Disease, Pharmaceutical industry, Vaccine

To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).

Key Points: 
  • To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA).
  • Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Rare disease and cancer patients depend upon high-risk, low-probability drug development that takes many years to develop and aims for cure.
  • One example is LYNPARZA® (olaparib), a small-molecule cancer medicine approved in 2014 in the US for a small group of late-line ovarian cancer patients.
  • Additional trials added small groups of breast and pancreatic cancer patients, with the most recent indication in prostate cancer approved just this year – nine years later.